Intraclass switching of interleukin-23 inhibitors in psoriasis: effectiveness, patterns and predictors of response – a retrospective multicentre study in Italy

Intraclass switching among IL-23 inhibitors is an effective strategy, with risankizumab emerging as the most favourable option.

Authors

Simone Ribero (ORCID: https://orcid.org/0000-0002-0098-1406)
Marco Manfredini (ORCID: https://orcid.org/0000-0003-3601-655X)
Matteo Megna (ORCID: https://orcid.org/0000-0003-1803-2046)
Emanuele Trovato (ORCID: https://orcid.org/0000-0001-8301-9206)
Serena Lembo (ORCID: https://orcid.org/0000-0001-9053-1793)
Martina Burlando (ORCID: https://orcid.org/0000-0002-4381-6718)
Gaia Moretta (ORCID: https://orcid.org/0000-0002-8839-5961)
Giacomo Caldarola (ORCID: https://orcid.org/0000-0002-8837-9232)
Andrea Carugno (ORCID: https://orcid.org/0000-0002-8231-2205)
Alessandro Giunta (ORCID: https://orcid.org/0000-0003-3589-9346)
Eleonora De Luca (ORCID: https://orcid.org/0000-0003-3893-2869)
Maria Letizia Musumeci
Anna Balato

University of Siena (IT)
Università Cattolica del Sacro Cuore (IT)
University of Insubria (IT)
University of Rome Tor Vergata (IT)
University of Modena and Reggio Emilia (IT)
University of Salerno (IT)
University of Campania "Luigi Vanvitelli" (IT)
Agostino Gemelli University Polyclinic (IT)
University of Catania (IT)
Istituto Dermopatico dell'Immacolata (IT)
University of Campania "Luigi Vanvitelli" (IT)
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli (IT)
Ospedale Policlinico San Martino (IT)
Istituti di Ricovero e Cura a Carattere Scientifico (IT)
University of Turin (IT)
University of Naples Federico II (IT)